Research Papers:

Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer

Carly J. King, Josha Woodward, Jacob Schwartzman, Daniel J. Coleman, Robert Lisac, Nicholas J. Wang, Kathryn Van Hook, Lina Gao, Joshua Urrutia, Mark A. Dane, Laura M. Heiser _ and Joshi J. Alumkal

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:111084-111095. https://doi.org/10.18632/oncotarget.22560

Metrics: PDF 760 views  |   HTML 1628 views  |   ?  


Carly J. King1, Josha Woodward2, Jacob Schwartzman2, Daniel J. Coleman2, Robert Lisac2, Nicholas J. Wang1, Kathryn Van Hook2, Lina Gao2, Joshua Urrutia2, Mark A. Dane1, Laura M. Heiser1,* and Joshi J. Alumkal2,*

1Department of Biomedical Engineering, OHSU Center for Spatial Systems Biomedicine, Oregon Health and Science University, Portland, OR 97239, USA

2Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA

*These authors have contributed equally to this work

Correspondence to:

Laura M. Heiser, email: heiserl@ohsu.edu

Joshi J. Alumkal, email: alumkalj@ohsu.edu

Keywords: prostate cancer; castration resistant; drug resistance; enzalutamide

Received: April 13, 2017    Accepted: September 29, 2017    Published: November 20, 2017


Recent work demonstrates that castration-resistant prostate cancer (CRPC) tumors harbor countless genomic aberrations that control many hallmarks of cancer. While some specific mutations in CRPC may be actionable, many others are not. We hypothesized that genomic aberrations in cancer may operate in concert to promote drug resistance and tumor progression, and that organization of these genomic aberrations into therapeutically targetable pathways may improve our ability to treat CRPC. To identify the molecular underpinnings of enzalutamide-resistant CRPC, we performed transcriptional and copy number profiling studies using paired enzalutamide-sensitive and resistant LNCaP prostate cancer cell lines. Gene networks associated with enzalutamide resistance were revealed by performing an integrative genomic analysis with the PAthway Representation and Analysis by Direct Reference on Graphical Models (PARADIGM) tool. Amongst the pathways enriched in the enzalutamide-resistant cells were those associated with MEK, EGFR, RAS, and NFKB. Functional validation studies of 64 genes identified 10 candidate genes whose suppression led to greater effects on cell viability in enzalutamide-resistant cells as compared to sensitive parental cells. Examination of a patient cohort demonstrated that several of our functionally-validated gene hits are deregulated in metastatic CRPC tumor samples, suggesting that they may be clinically relevant therapeutic targets for patients with enzalutamide-resistant CRPC. Altogether, our approach demonstrates the potential of integrative genomic analyses to clarify determinants of drug resistance and rational co-targeting strategies to overcome resistance.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22560